Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT02598297
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02593760
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Oncology Hematology Care Inc, Cincinnati, Ohio, United States
🇺🇸Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT02593929
Study of INCB053914 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 97
- Registration Number
- NCT02587598
- Locations
- 🇺🇸
Texas Oncology, Tyler, Texas, United States
🇺🇸Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸UC Davis comprehensive Cancer Center, Sacramento, California, United States
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 207
- Registration Number
- NCT02577926
- Locations
- 🇩🇪
Universitätsklinikum Ulm Klinik für Innere Medizin III, Ulm, Baden-Württemberg, Germany
🇩🇪Rems-Murr Klinikum Winnenden, Winnenden, Baden-Württemberg, Germany
🇩🇪Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie, Mannheim, Baden-Württemberg, Germany
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02494882
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT02493530
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Mays Cancer Center at University of Texas Health San Antonio, San Antonio, Texas, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT02475655
- Locations
- 🇺🇸
Weill Cornell Chelsea CRS, New York, New York, United States
🇺🇸Alabama CRS, Birmingham, Alabama, United States
🇺🇸Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02436135
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT02400463
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.